This week's roundup of Houston innovators includes Anwar Sadek of Corrolytics, Angela Holmes of OmniScience, and Eduardo Fonseca of EndoQuest Robotics. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three innovators across health care and energy.

Anwar Sadek, founder and CEO of Corrolytics

Anwar Sadek of Corrolytics joins the Houston Innovators Podcast to discuss his company's growth and move to Houston. Photo courtesy

Despite having success in taking his technology from lab to commercialization, Anwar Sadek made the strategic decision to move his company, Corrolytics, from where it was founded in Ohio to Houston.

"Houston is the energy capital of the world. For the technology we are developing, it is the most strategic move for us to be in this ecosystem and in this city where all the energy companies are, where all the investors in the energy space are — and things are moving really fast in Houston in terms of energy transition and developing the current infrastructure," Sadek, co-founder and CEO of Corrolytics, says on the Houston Innovators Podcast.

And as big as a move as it was, it was worth it, Sadek says.

"It's been only a year that we've been here, but we've made the most developments, the most outreach to clients in this one last year." Continue reading.

Angela Holmes, CEO of OmniScience

Angela Holmes is the CEO of OmniScience. Photo via omniscience.com

Houston data science firm OmniScience announced this month that it has partnered with Florida-based INmune Bio (NASDAQ: INMB) on a global Phase 2 Alzheimer’s disease clinical trial.

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time, according to a release. The two companies also partnered during Vivo’s development and recent roll-out.

"OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” Angela Holmes, CEO of OmniScience, says in a statement. “As our partnership moves forward, we’re gaining further insights from the INmune team that we can integrate into Vivo’s roadmap. We look forward to our continued mutual success.” Continue reading.

Eduardo Fonseca, interim CEO of EndoQuest Robotics

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via LinkedIn

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time. Photo omniscience.bio

Houston AI data firm partners on Alzheimer’s clinical trial

now testing

Houston data science firm OmniScience announced this month that it has partnered with Florida-based INmune Bio (NASDAQ: INMB) on a global Phase 2 Alzheimer’s disease clinical trial.

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time, according to a release. The two companies also partnered during Vivo’s development and recent roll-out.

"OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” Angela Holmes, CEO of OmniScience, says in a statement. “As our partnership moves forward, we’re gaining further insights from the INmune team that we can integrate into Vivo’s roadmap. We look forward to our continued mutual success.”

The ADO2 trial will investigate INmune Bio's clinical-stage biotechnology XPro in patients with mild cognitive impairment or Alzheimer’s disease with brain inflammation, according to its website. Its products are focused on "restoring function in the body's innate immune system to fight disease."

The trial is overenrolled with 208 patients diagnosed with mild Alzheimer’s disease or mild cognitive impairment. The top-line results are expected to be released in Q2 2025.

"A global trial of this size is vast, and Vivo will be critical in our ability to analyze cognitive results,” Tara Lehner, INmune Bio’s vice president of clinical operations, says in the statement. “With genAI provided by Vivo, we can amplify our clinical teams’ capabilities, turning complex data into actionable insights at unprecedented speed, which means we can get answers—and treatments—to patients faster.”

INmune will be able to use OmniScience's Vivo product to unify data from electronic data capture, clinical trial management systems, patient-reported outcomes, clinical outcome assessments, labs, wearables, safety databases and more, according to the statement. The product has been shown to improve data quality and visualizations and reduce the reliance on spreadsheet-based data analysis during clinical trials.

Omniscience was originally founded in 2017, then known as Mercury Data Science. It rebranded and changed its name earlier this year. Holmes was named CEO in 2022.

Omniscience's Vivo product recently won first place in the CNS Summit 2024 Innovation Showcase in Boston and the Blue Whale Ribbon at the inaugural Whale Tank pitch competition during the 2024 Innovation Network Gathering (ING) in West Chester, Pennsylvania.

This week's roundup of Houston innovators includes Angela Holmes of Omniscience, David Pruner of TEX-E, and Jessica Traver of IntuiTap. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Angela Holmes, CEO of OmniScience

Angela Holmes is the CEO of OmniScience. Photo via omniscience.com

A Houston organization established to provide critical data science support to its clients has rebranded and entered into its latest era.

Mercury Data Science has officially rebranded as OmniScience. Founded in 2017 as a spin off of Mercury, a local venture capital group, the data science-focused software company is led by CEO Angela Holmes, who was named to the position in 2022.

"OmniScience signifies our commitment to being a force of innovation in data science and life sciences," Holmes says in the release. "The new brand mirrors our vision for the future, where data science is a driving force for positive change in life sciences." Read more.

David Pruner, executive director of TEX-E

David Pruner, executive director of TEX-E, joins the Houston Innovator Podcast. Photo via LinkedIn

Collaboration is the name of the game for David Pruner, executive director of the Texas Entrepreneurship Exchange for Energy, known as TEX-E, a nonprofit housed out of Greentown Labs that was established to support energy transition innovation at Texas universities.

TEX-E launched in 2022 in collaboration with Greentown Labs, MIT’s Martin Trust Center for Entrepreneurship, and five university partners — Rice University, Texas A&M University, Prairie View A&M University, University of Houston, and The University of Texas at Austin.

Pruner was officially named to his role earlier this year, but he's been working behind the scenes for months now getting to know the organization and already expanding its opportunities from students across the state at the five institutions.

"In the end, we have five different family members who need to be coordinated differently," Pruner says on the Houston Innovators Podcast. "There's plenty of bright students at each of these schools, and there's plenty of innovation going on, it's whether it can grow, prosper, and be sustainable." Read more.

Houston health tech startup revolutionizing spinal taps receives FDA clearance

Co-founded by CEO Jessica Traver, IntuiTap says it plans to roll out the device at U.S. hospitals within the next year. Photo courtesy of IntuiTap

Houston startup IntuiTap Medical has gained clearance from the U.S. Food and Drug Administration for its VerTouch medical device.

The company says VerTouch is designed to make spinal punctures more accurate and consistent. The handheld imaging tool helps health care providers perform spinal punctures at a patient’s bedside.

IntuiTap says it plans to roll out the device at U.S. hospitals within the next year. The company is mulling global partnerships to help launch VerTouch.

Jessica Traver, co-founder and CEO of IntuiTap, says the FDA clearance “marks a crucial milestone in our team’s journey to making epidurals, spinals, and lumbar punctures more accurate and efficient.” Read more.

Mercury Data Science has officially rebranded as OmniScience. Photo via Getty Images

Houston data science firm rebrands to focus on the intersection of AI and life science

introducing OmniScience

A Houston organization established to provide critical data science support to its clients has rebranded and entered into its latest era.

Mercury Data Science has officially rebranded as OmniScience. Founded in 2017 as a spin off of Mercury, a local venture capital group, the data science-focused software company is led by CEO Angela Holmes, who was named to the position in 2022.

"OmniScience signifies our commitment to being a force of innovation in data science and life sciences," Holmes says in the release. "The new brand mirrors our vision for the future, where data science is a driving force for positive change in life sciences."

Angela Holmes is the CEO of OmniScience. Photo via mercuryds.com

Per the news release, the rebranding aligns the company with its mission of supporting innovation at the intersection of biology and data science. The new name reflects the combination of "omniscient" and "science," according to the company.

OmniScience's technology helps its customers across the life science spectrum with navigating key data insights for clinical trials, purpose-built AI development, and other data science services, according to its website.

"This rebrand represents more than just a name change; it signals a bold step into the future, where OmniScience will play a pivotal role in shaping the data science landscape in life sciences," reads the release.

The firm is based out of Texas Medical Center Innovation and has over 20 employees listed on the website.

This week's roundup of Houston innovators includes Angela Holmes of Mercury Data Science, Meredith Wheeler and Maggie Segrich of Sesh Coworking, and Shaun Zhang of the University of Houston. Courtesy photos

4 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from data science to cancer therapeutics — recently making headlines in Houston innovation.

Angela Holmes, CEO of Mercury Data Science

Angela Holmes is the CEO of MDS. Photo via mercuryds.com

A Houston-based AI solutions consultancy has made changes to its C-suite. Dan Watkins is passing on the CEO baton to Angela Holmes, who has served on MDS's board and as COO. As Holmes moves into the top leadership position, Watkins will transition to chief strategy officer and maintain his role on the board of directors.

"It is an exciting time to lead Mercury Data Science as we advance the development of innovative data science platforms at the intersection of biology, behavior, and AI," says Holmes in the release. "I am particularly excited about the demand for our Ergo insights platform for life sciences, allowing scientists to aggregate a vast set of biomedical data to better inform decisions around drug development priorities." Click here to read more.

Meredith Wheeler and Maggie Segrich, co-founders of Sesh Coworking

Sesh Coworking and its founders Maggie Segrich and Meredith Wheeler are on a roll. Photo courtesy of Sesh

Sesh Coworking, described as Houston’s first female-focused and LGBTQIA+ affirming coworking, has been operating its 2808 Caroline Street location's second-floor space since January, but the first floor, as of this week, is now open to membership and visitors. The new build-out brings the location to over 20,000 square feet of space.

Called The Parlor, the new space includes additional desks, common areas, a wellness room, and a retail pop-up space. Since its inception in early 2020, Sesh has overcome the pandemic-related obstacles in its path and even seen a 60 percent increase in membership with an overall 240 percent increase in sales over the past year.

“Our growth is a testament to the ever-changing landscape of Houston’s office and retail industry after the workplace dramatically changed in 2020,” says Maggie Segrich, co-founder of Sesh Coworking, in a news release. “We are ecstatic to welcome current and prospective members to our new, inclusive space.” Click here to read more.

The duo also joined the Houston Innovators Podcast to discuss Sesh's growth. Click here to listen.

Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston

A UH professor is fighting cancer with a newly created virus that targets the bad cells and leaves the good ones alone. Photo via UH.edu

A Houston researcher is developing a cancer treatment — called oncolytic virotherapy — that can kill cancer cells while being ineffective to surrounding cells and tissue. Basically, the virus targets the bad guys by "activating an antitumor immune response made of immune cells such as natural killer (NK) cells," according to a news release from the University of Houston.

However exciting this rising OV treatment seems, the early stage development is far from perfect. Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston, is hoping his work will help improve OV treatment and make it more effective.

“We have developed a novel strategy that not only can prevent NK cells from clearing the administered oncolytic virus, but also goes one step further by guiding them to attack tumor cells. We took an entirely different approach to create this oncolytic virotherapy by deleting a region of the gene which has been shown to activate the signaling pathway that enables the virus to replicate in normal cells,” Zhang says in the release. Click here to read more.

A new report on best markets for startup compensation — and more Houston innovation news. Photo via Getty Images

Data science firm names new exec, how Houston ranks for startup compensation, and more local innovation news

short stories

Houston's summer has been heating up in terms of innovation news, and there might be some headlines you may have missed.

In this roundup of short stories within Houston startups and tech, a Houston unicorn is reportedly opening a new facility, a data science organization names new CEO, and more.

Mercury Data Science names new CEO

Angela Holmes, former COO of Mercury Data Science, has been named the CEO. Photo courtesy of MDS

A Houston-based AI solutions consultancy has made changes to its C-suite. Dan Watkins is passing on the CEO baton to Angela Holmes, who has served on MDS's board and as COO. As Holmes moves into the top leadership position, Watkins will transition to chief strategy officer and maintain his role on the board of directors.

"Over the last three years, as COO and a member of the board of directors, Angela has been instrumental in MDS’s growth, especially in building MDS’s Strategy Consulting practice and UI/UX and Machine Learning Engineering capabilities," saus Watkins in a news release. "The magic at Mercury Data Science is all about the diverse team who have created a culture of excellence, trust and purpose with the goal of using AI/ML to solve some of the most important health and social problems facing the world today.

"Angela was instrumental in building our culture and customer base over the last three years and will do a great job taking the company to the next level," he continues.

Mercury Data Science was incubated and launched out of Houston-based VC firm Mercury Fund. MDS works with the Mercury portfolio companies as well other startups in the life sciences and health care space.

"It is an exciting time to lead Mercury Data Science as we advance the development of innovative data science platforms at the intersection of biology, behavior, and AI," says Holmes in the release. "I am particularly excited about the demand for our Ergo insights platform for life sciences, allowing scientists to aggregate a vast set of biomedical data to better inform decisions around drug development priorities.

"The increasing understanding of biology, accessibility of large data sets, and accelerating computational capabilities is creating a golden age of life science innovation," she adds. "We are committed to using our expertise to accelerate our clients’ advances in human health, nutrition, therapeutics, diagnostics, and behavior, to create profound advances for humanity."

Here's how Houston ranks in terms of startup compensation

This chart from Carta shows the four tiers of the US markets. Houston, in 15th place, leads the third tier. Image courtesy of Carta

A new report looked into compensation at startups across the country, and the Texas market fared pretty well overall. The report from Carta, a San Francisco, California-based technology company that specializes in capitalization table management and valuation software, factored in data using more than 127,000 employee records from startups that use Carta Total Comp, the premier compensation management platform for private companies.

"At Carta, we see it as our responsibility to share the insights that come from an unmatched amount of data about the private market," per the report. "That includes data on startup headcount, payroll and equity metrics, salary medians, and remote work."

The greater Houston area ranked No. 15 in the list, which lands it at the top of the third tier just ahead of Dallas. As the chart depicts, Houston has 88 percent of the compensation of the top market — which this year is a four-way tie between the San Francisco, New York, San Jose, and Seattle areas. Austin landed in the middle of the top tier, and San Antonio snuck into the bottom of the third tier. The full report with national trends is online.

Axiom to open in former electronics store space

Axiom Space will reportedly move engineering into a former retail space. Photo via Facebook

According to a Facebook post from Deer Park Economic Development, Houston unicorn startup Axiom Space has leased a 146,000-square-foot space in what used to be a Fry's Electronics store in Webster. Reportedly, the new facility will house its engineering operations.

"Axiom's initial plans for the building are to support 400 employees, all assigned to engineering work on the Axiom Station, including development across all of its subsystems," reads the post from July 6. "The buildout will be able to accommodate up to 540 people. Axiom plans a move in late July or early August."

Axiom hasn't put out an official news release on this particular facility, but in May the company broke ground on its headquarters at Ellington Airport, the site of the Houston Spaceport. That campus just down the street will house employee offices, astronaut training, and mission control facilities, engineering development and testing labs, and a high bay production facility to house Axiom’s space station modules under construction, according to Axiom.

TRISH awards three postdoctoral fellowships to further space health research

Three scientists were tapped for funding from this Houston organization. Photo via Pexels

Baylor College of Medicine's Translational Research Institute for Space Health — along with its partners California Institute of Technology and Massachusetts Institute of Technology — announced the new fellowship cohort of postdoctoral researchers supported by the TRISH Academy of Bioastronautics who will receive funding and resources for further career growth for two years.

“Cultivating the next generation of space health researchers is one of our strategic goals,” says Dr. Dorit Donoviel, TRISH executive director and associate professor in Baylor’s Center for Space Medicine, in a news release. “We aim to prepare a diverse workforce from a variety of scientific backgrounds to help us solve the challenges facing space explorers on future missions to the Moon and beyond. We are thrilled to welcome this next batch of postdocs as they help bring us closer to that goal.”

These fellows join a cohort of more than 20 previously supported TRISH postdoctoral researchers.

"My career was launched with a fellowship from the National Space Biomedical Research Institute (NSBRI), the predecessor to TRISH, so I greatly appreciate the value of mentorship and community to those starting out in the field of space biomedical research,” says Dr. Jeffrey Willey, associate professor of radiation oncology at Wake Forest University School of Medicine, in the release.

This 2022 postdoctoral fellows and their research projects are:

  • Xu Cao —Identifying Genetic Factors in Radiation Injury with Pooled Single Cell Sequencing
  • Ashley Nemec-Bakk — The Use of Two New Ground-based Models of Deep Space Travel to Study the Role of Mitochondria and Oxidative Stress in Cardiovascular Effects
  • David Temple — Systematically Assessment of Noisy Galvanic Vestibular Stimulation as a Sensorimotor Countermeasure

Greentown Labs announces second carbon innovation cohort

Greentown Labs announced its latest carbon-focused cohort. Photo via GreentownLabs.com

The The Carbon to Value Initiative is a multi-year collaboration between the Urban Future Lab at NYU Tandon School of Engineering, Greentown Labs, and Fraunhofer USA, which is supported by the New York State Energy Research and Development Authority. In its second year, the carbontech accelerator program has selected eight startups in partnership with Fluor Corporation, the initiative’s Year Two Cohort Champion.

With almost 100 applicants from about 20 countries, the C2V Initiative named the following startups to the program, per a release from Greentown:

  • Aluminum Technologies (New Orleans, U.S.) has developed Carbo-Chloride Reduction (CCR) aluminum manufacturing technology, which captures process CO2 and also reduces power consumption relative to conventional methods.
  • Carbon Upcycling Technologies (Calgary, Canada) utilizes point-source CO2 and mineralizes it with waste materials to create supplementary cementitious materials (SCMs) that can be used in building materials.
  • Carbonova Corp (Calgary, Canada) utilizes CO2 and methane as a feedstock to produce carbon nanofibers (CNF) that may be used in various fields such as transportation and buildings.
  • ecoLocked (Berlin, Germany) converts waste biomass into biochar to create admixes that can replace a share of the cement used in concrete manufacturing, and thus sequester carbon within buildings.
  • Full Cycle Bioplastics (San Jose, U.S.) has a patented bacteria-based technology that converts organic waste into Polyhydroxyalkanoate (PHA), a biopolymer that can be used to replace a wide range of oil-based plastic applications.
  • Lydian (Somerville, U.S.) develops an electro-thermal reactor technology that converts captured CO2 into fuels and chemicals.
  • Molecule Works (Richland, U.S.) develops a solid sorbent Direct Air Capture (DAC) system using a novel reactor and contactor configuration.
  • Osmoses (Boston, U.S.) develops polymers for gas separation, enabling membrane-based carbon capture applications.

“If we are to succeed in reaching carbon neutrality, then carbontech must play a critical role,” says Ryan Dings, COO and general counsel of Greentown Labs. “For carbontech to do so, we must convene entrepreneurs, market leaders, investors, and policymakers deeply committed to rapidly creating a carbontech ecosystem, which is what our efforts with the C2V Initiative represent and why we’re so proud to be working with this incredible group of partners.”

While the program and its cohort companies aren't based in Houston, Greentown's local presence and member companies will play a role in the initiative.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.